Infusible Platelet Membrane versus Conventional Platelet Concentrate: Benefits and Disadvantages

Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 2

Abstract

Blood transfusion centers are under considerable pressure to produce platelet concentrates with a shelf life limit of 3 to 5 days. Many approaches have been investigated experimentally to produce new hemostatically active platelet products that are capable of long term storage. In this article infusible platelet membrane will be explained as a platelet substitute versus conventional liquid-stored platelet concentrates with regard to their benefits and disadvantages in transfusion medicine. This review shows that lyophilized infusible platelet membrane as a platelet substitute might offer many important benefits over common platelet concentrates with few disadvantages. Infusible platelet membrane may have efficacy, safety and acceptable tolerability without thrombogenecity, immunogenicity or toxicity. The other main benefits of this product are improved shelf life, ease of storage, high-precision dose calculation, easy reformulation, reduced viral and bacterial load, decreased refractoriness to platelet transfusion, reduced contaminating red and white blood cells, reduced side effects due to removal of undesirable effects of intracellular and extracellular proinflamatory mediators and removal of platelet-derived microparticlecs as a source of CD40/CD40L ligands, which can enhance post-transfusion reactions, achieving hemostatic response without increasing the circulating platelet count, not being removed from circulation by immune mechanisms or sepsis and not requiring blood typing. In spite of these benefits, there are still some difficulties in demonstrating its efficacy, short-term circulation and hemostatic function. Therefore, further human clinical studies will be needed to fully define the exact role of infusible platelet membrane in the management of patients with thrombocytopenia. Keywords: Infusible platelet membrane, platelet, substitute, platelet concentrates, side effects.

Authors and Affiliations

Saleh Nasiri, Mir Kamran Mousavi Hosseini

Keywords

Related Articles

Carcinosarcoma of Stomach with Chondroblastic Differentiation: A Rare Case and Review of Literature

Gastric carcinosarcoma is a rare cancer of adults with poor prognosis compared with other gastric malignancies. To the best of our knowledge, the present report is the first case of gastric carcinosarcoma with chondrobla...

Amantadine Plus Interferon-α Versus Interferon-α Monotherapy for the Treatment of Chronic Hepatitis-C Infection in β-Thalassemia Major Patients: A Randomized Double Blinded Pilot Study in Shiraz, Iran

Background: Hepatitis-C infection is a major problem in chronically transfused patients. We compared Interferon-α (INF-α) monotherapy with combination of INF-α and amantadine in the treatment of β-thalassemia major patie...

Breast Cancer Associated with Dermatomyositis

Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy with characteristic skin lesions. Case series have shown an association between dermatomyositis and malignancy. Malignancy has been found in 15-25% of the a...

Co-inheritance of α-and β-thalassemia: challenges in prenatal diagnosis of thalassemia

Background: The double heterozygous state of α/β thalassemia may alter the hematological indices and modify the phonotype. In addion, definite characterizaon of co-inheritance of α- and β-thalassemia heterozygous carri...

Knowledge of Breast Cancer Risk Factors among a Cohort of Nurses in Iran

Background: Improving the knowledge of healthcare providers towards different aspects of breast cancer leads to appropriate management and screening of disease. This study aimed to investigate the knowledge of breast can...

Download PDF file
  • EP ID EP364758
  • DOI -
  • Views 92
  • Downloads 0

How To Cite

Saleh Nasiri, Mir Kamran Mousavi Hosseini (2014). Infusible Platelet Membrane versus Conventional Platelet Concentrate: Benefits and Disadvantages. Iranian Journal of Blood and Cancer, 6(2), 87-93. https://www.europub.co.uk/articles/-A-364758